T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2126
Dyne Therapeutics
DYN
$4.85B
| $493K | ﹤0.01% |
38,708
+2,148
| +6% | +$24.6K |
|
|
RWT
2127
Redwood Trust
RWT
$599M
| $492K | ﹤0.01% |
85,673
+11,581
| +16% | +$89.5K |
|
2128
iHeartMedia
IHRT
$464M
| $491K | ﹤0.01% |
66,858
+25,334
| +61% | +$219K |
|
|
POSH
2129
DELISTED
Poshmark, Inc. Class A Common Stock
POSH
| $489K | ﹤0.01% |
31,183
-1,354,571
| -98% | -$16.1M |
|
2130
Oxford Industries
OXM
$542M
| $487K | ﹤0.01% |
5,420
-104,276
| -95% | -$10.1M |
|
|
MGI
2131
DELISTED
MoneyGram International, Inc. New
MGI
| $487K | ﹤0.01% |
46,802
+8,678
| +23% | +$89.4K |
|
2132
Deluxe
DLX
$1.11B
| $484K | ﹤0.01% |
29,013
+3,245
| +13% | +$68.2K |
|
2133
Microvision
MVIS
$89.7M
| $484K | ﹤0.01% |
8,934
+642
| +8% | +$45.4K |
|
|
SFIX
2134
Stitch Fix
SFIX
$487M
| $484K | ﹤0.01% |
122,244
-66,436
| -35% | -$377K |
|
|
IMGN
2135
DELISTED
Immunogen Inc
IMGN
| $482K | ﹤0.01% |
100,823
+52,410
| +108% | +$276K |
|
|
HOUS
2136
DELISTED
Anywhere Real Estate
HOUS
| $481K | ﹤0.01% |
59,276
+13,382
| +29% | +$137K |
|
|
KNBE
2137
DELISTED
KnowBe4, Inc. Class A Common Stock
KNBE
| $480K | ﹤0.01% |
23,054
+4,804
| +26% | +$88.5K |
|
2138
Vericel Corp
VCEL
$2.28B
| $479K | ﹤0.01% |
20,643
+3,097
| +18% | +$84.5K |
|
|
RETA
2139
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $479K | ﹤0.01% |
19,046
-481,724
| -96% | -$13.4M |
|
|
BCLI
2140
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $478K | ﹤0.01% |
7,200
+1,000
| +16% | +$50.2K |
|
|
DMC
2141
Del Monte Corp
DMC
$1.44B
| $478K | ﹤0.01% |
20,552
+1,841
| +10% | +$51.3K |
|
|
PLL
2142
DELISTED
Piedmont Lithium
PLL
| $478K | ﹤0.01% |
+8,922
| New | +$459K |
|
2143
Sinclair Inc
SBGI
$1.03B
| $478K | ﹤0.01% |
26,419
+2,433
| +10% | +$54K |
|
2144
Simulations Plus
SLP
$370M
| $477K | ﹤0.01% |
9,810
-1,173
| -11% | -$68.5K |
|
2145
Geron
GERN
$982M
| $476K | ﹤0.01% |
203,290
+22,009
| +12% | +$49.3K |
|
2146
Energy Recovery
ERII
$399M
| $471K | ﹤0.01% |
21,631
+3,506
| +19% | +$78.9K |
|
2147
Funko
FNKO
$335M
| $470K | ﹤0.01% |
23,229
+1,891
| +9% | +$43.3K |
|
|
OPI
2148
DELISTED
Office Properties Income Trust
OPI
| $470K | ﹤0.01% |
33,409
+5,431
| +19% | +$102K |
|
2149
Ethan Allen Interiors
ETD
$583M
| $468K | ﹤0.01% |
22,135
+1,344
| +6% | +$31.4K |
|
2150
Beyond Meat
BYND
$210M
| $467K | ﹤0.01% |
32,888
+5,779
| +21% | +$159K |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.